Clinical Trials Logo

Smoking clinical trials

View clinical trials related to Smoking.

Filter by:

NCT ID: NCT02190643 Completed - Smoking Clinical Trials

Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers

Start date: April 2013
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate a smoking cessation program for Latino HIV-positive smokers focused on improving adherence to using the nicotine skin patch.

NCT ID: NCT02188459 Completed - Smoking Clinical Trials

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

BIBS
Start date: October 30, 2014
Phase: Phase 2
Study type: Interventional

Smoking during pregnancy adversely affects the health of the mother and her developing baby. Maternal smoking approximately doubles the risk of miscarriage, placental complications, preterm delivery, low birth weight and fetal and newborn death. The most common adverse effect of smoking during pregnancy is low birth weight, which sharply increases the risk of the newborn becoming ill or dying. In the US, maternal smoking is responsible for 30% of low birth weight babies, 10% of premature deliveries, and 5% of infant deaths. Fortunately, smoking cessation by pregnancy week 16, or as late as the third trimester, results in a near-normal weight infant at birth. Even reductions in smoking increase birth weight. Despite the known risks, the majority of women who are smoking at the time of their first prenatal visit continue to smoke. Bupropion is approved by the US Food and Drug Administration (FDA) for smoking cessation in people who are not pregnant, but there are no carefully controlled studies on the use of Bupropion to help pregnant women quit smoking. Bupropion is also FDA approved to treat depression, and some pregnant women have taken it for that purpose, even though it has not been formally tested. The investigators propose to conduct a randomized, parallel-group, double-blinded, placebo-controlled, 10 week trial of Bupropion in 360 pregnant women who smoke daily and wish to quit smoking. The study has three primary hypotheses. First, the investigators hypothesize that Bupropion treated subjects will decrease the frequency of smoking more than placebo-treated subjects. Second the investigators hypothesize that Bupropion treated subjects will have greater positive pregnancy and child health outcomes than placebo-treated subjects. Third the investigators hypothesize that Bupropion treated subjects will have decreased frequency of depressive symptoms and cigarette craving than placebo-treated subjects. These finding will provide information on the safety and efficacy of bupropion treat for smoking cessation in pregnant women.

NCT ID: NCT02188446 Completed - Bladder Cancer Clinical Trials

Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients

STOP-OP
Start date: November 2014
Phase: N/A
Study type: Interventional

Radical cystectomy provides the best cancer-specific survival for muscle-invasive urothelial cancer. However the postoperative morbidity remains at 11-68 %. Smoking and alcohol consumption above two drinks per day is associated with an increased risk of postoperative morbidity. Six-eight weeks of smoking and alcohol abstinence prior to elective surgery is recommended to reduce this risk, but for cancer patients the preoperative period is often very short. This randomised clinical trial (STOP-OP) will reach a conclusion on the effect of a new Gold Standard Programme for both smoking and alcohol cessation Intervention using the Gold Standard Programme (GSP) on the frequency and severity of postoperative complications after bladder cancer surgery.

NCT ID: NCT02185898 Completed - Smoking Clinical Trials

Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes

Start date: May 2014
Phase: N/A
Study type: Interventional

This study will assess environmental emissions of selected compounds in a test chamber after cigarette smoking or e-cigarette vaping.

NCT ID: NCT02183818 Completed - COPD Clinical Trials

Integrative-omics of the Disordered COPD Small Airway Epithelium

Start date: April 6, 2015
Phase:
Study type: Observational

We aim to use an integrated network systems approach to analyze certain existing small airway epithelium (SAE) omic data sets at the genetic, epigenetic (methylation), gene expression, microRNA and metabolomic levels, to develop an initial model of network connectivities and key network pressure points relevant to SAE biology in health and disease.

NCT ID: NCT02173938 Completed - Smoking Clinical Trials

Novel Psychosocial Influences on Smoking Cessation

Start date: August 2012
Phase: N/A
Study type: Observational

Our overall research goal is to determine how these novel psychosocial factors impact cessation. This pilot study will answer how dual use of other tobacco products, direct to consumer marketing, and the new phenomenon of butting-out and relighting influences cessation, and how understanding impulsivity and task persistence could lead to new and improved behavioral interventions for tobacco dependence. Answers to these pilot questions will lead to the publication of several manuscripts and provide important feasibility data to design large, well-powered clinical trials, population-level epidemiological studies, and contribute to furthering the field of tobacco treatment.

NCT ID: NCT02168855 Completed - Smoking Clinical Trials

Cessation in Non-Daily Smokers

QUITS
Start date: June 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of as-needed oral Nicotine Replacement Therapy (NRT) - 2 mg nicotine gum - for smoking cessation in non-daily, or intermittent, smokers, and to study the process of relapse in ITS, using Ecological Momentary Assessment (EMA).

NCT ID: NCT02168673 Completed - COPD Clinical Trials

Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke

Start date: April 2011
Phase: N/A
Study type: Observational

Cigarette smoking is the major risk factor for developing chronic obstructive pulmonary disease (COPD). Patients with COPD have difficulty clearing mucus and debris from their airways. Even smokers who have not developed COPD may have difficulty clearing the airways. This is partly because smoking impairs the function of cilia, tiny hairs lining the airways that sweep out mucus to keep the airways clean. The investigators have found that smoking reduces the length of cilia, which may contribute to the worsened cilia function in smoking and COPD. This is true even in smokers who show no signs of lung disease. The investigators believe that smoking affects levels of genes in lung cells, resulting in shorter cilia.

NCT ID: NCT02167295 Completed - Smoking Clinical Trials

Biobehavioral and Cultural Determinants of Betel Quid Chewing, Dependence, and Withdrawal in Taiwan

BCDBQCDWT
Start date: December 2012
Phase: N/A
Study type: Observational

Cancer of the oral cavity is one of the fastest growing cancers among men in Taiwan. Previous research has established a strong link between betel quid chewing, a common practice among Taiwanese men, and oral cancer. However, despite the strong association, no attempt has been made to develop behavioral measures to facilitate betel quid cessation. This application extends upon existing collaboration between MD Anderson and China Medical University Hospital (CMUH) and seeks to characterize betel quid chewers and their withdrawal symptoms, in order to address an urgent cancer epidemiology issue in Taiwan.

NCT ID: NCT02164383 Completed - Smoking Cessation Clinical Trials

A Quit Smoking Study Using Smartphones

Start date: October 2014
Phase: N/A
Study type: Interventional

The objective of this research is to determine whether smartphone games show promise for helping smokers increase their chances of quitting. The central hypothesis is that smokers who have access to smartphone games during their quit smoking attempt will smoke fewer cigarettes and report less craving than will smokers without such access.